Stryker Corp stock (US8636671013): ABN AMRO sells 78,873 shares

ABN AMRO Bank N.V. sold 78,873 shares of Stryker Corp on May 11, 2026, amid stable trading and recent M&A activity including the Amplitude Vascular Systems acquisition.

Stryker Corp shares saw institutional activity as ABN AMRO Bank N.V. disclosed selling 78,873 shares of the medical technology company on May 11, 2026, according to MarketBeat as of 05/11/2026. The stock traded around 385 USD on Nasdaq recently, with a 0.72% gain noted in historical data. Stryker also completed its acquisition of Amplitude Vascular Systems, entering the intravascular lithotripsy market, per GSCapitalConnect as of 05/11/2026.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Stryker Corp.
• Sector/industry: Medical Technology
• Headquarters/country: United States
• Core markets: Orthopaedics, MedSurg, Neurotechnology
• Key revenue drivers: Surgical equipment, implants
• Home exchange/listing venue: Nasdaq (SYK)
• Trading currency: USD

Stryker Corp: core business model

Stryker Corp develops and manufactures medical technology products, focusing on orthopaedics, medical and surgical equipment, and neurotechnology. The company serves hospitals and healthcare providers globally, with a strong US presence. Its portfolio includes joint replacement systems and surgical tools, driving recurring revenue through innovation.

Main revenue and product drivers for Stryker Corp

Key drivers include orthopaedics implants and Mako SmartRobotics for robotic-assisted surgery. MedSurg products like endoscopes and the Amplitude Vascular Systems acquisition bolster peripheral vascular offerings. Quarterly revenue rose 2.6% year-over-year, with net margin at 13.20% and return on equity at 23.42%, per MarketBeat as of 05/11/2026.

Industry trends and competitive position

The medtech sector sees growth in robotics and minimally invasive procedures. Stryker's Mako system provides a competitive edge in orthopaedics, locking in hospital ecosystems. Recent M&A like Amplitude Vascular Systems positions it in intravascular lithotripsy amid rising demand for vascular treatments.

Why Stryker Corp matters for US investors

Listed on Nasdaq, Stryker derives significant revenue from the US healthcare market. Exposure to elective procedures and aging demographics ties it to US economic health, making it relevant for investors tracking medtech growth.

Conclusion

Stryker Corp shows steady financials with recent institutional selling by ABN AMRO and strategic acquisition of Amplitude Vascular Systems. Trading stability around 385 USD reflects medtech resilience. Investors monitor ongoing revenue growth and sector trends for US market exposure.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.